Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Возможности нового блокатора рецепторов к ангиотензину в улучшении контроля артериальной гипертонии. Международное многоцентровое наблюдательное неинтервенционное проспективное исследование применения азилсартана медоксомила у пациентов с артериальной гип
Возможности нового блокатора рецепторов к ангиотензину в улучшении контроля артериальной гипертонии. Международное многоцентровое наблюдательное неинтервенционное проспективное исследование применения азилсартана медоксомила у пациентов с артериальной гип
Жернакова Ю.В., Чазова И.Е. Возможности нового блокатора рецепторов к ангиотензину в улучшении контроля артериальной гипертонии. Международное многоцентровое наблюдательное неинтервенционное проспективное исследование применения азилсартана медоксомила у пациентов с артериальной гипертонией и избыточной массой тела или ожирением в Российской Федерации и Республике Казахстан. Системные гипертензии. 2016; 13 (3): 6–12.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В настоящее время есть данные, свидетельствующие о достаточно низкой эффективности антигипертензивной терапии, особенно у пациентов с ожирением и метаболическими нарушениями, что свидетельствует о необходимости поиска новых высокоэффективных антигипертензивных средств, обладающих дополнительными возможностями в предотвращении поражения органов-мишеней и развития сердечно-сосудистых осложнений. На российском фармацевтическом рынке антигипертензивных препаратов представлен блокатор рецепторов к ангиотензину – азилсартана медоксомил (Эдарби®). В статье представлен дизайн исследования эффективности применения азилсартана медоксомила у пациентов с артериальной гипертонией и избыточной массой тела или ожирением в повседневной клинической практике Российской Федерации и Республики Казахстан.
Ключевые слова: артериальная гипертония, ожирение, метаболические нарушения, азилсартана медоксомил, Эдарби®.
Key words: arterial hypertension, obesity, metabolic disorders, azilsartan medoxomil, Edarbi®.
Ключевые слова: артериальная гипертония, ожирение, метаболические нарушения, азилсартана медоксомил, Эдарби®.
________________________________________________
Key words: arterial hypertension, obesity, metabolic disorders, azilsartan medoxomil, Edarbi®.
Полный текст
Список литературы
1. Ezzati M et al. Contributions of risk factors and medical care to cardiovascular mortality trends. Nat. Rev Cardiol 2015. doi:10.1038/nrcardio.2015.82
2. Lewington S, Clarke R, Qizibash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adult in 61 prospective studies. Lancet 2002; 360: 1903–13.
3. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (Issue 9623): 1513–8.
4. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. от имени исследователей. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваск. терапия и профилактика. 2014; 13 (4): 4–14. / Boitsov S.A., Balanova Iu.A., Shal'nova S.A. i dr. ot imeni issledovatelei. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovask. terapiia i profilaktika. 2014; 13 (4): 4–14. [in Russian]
5. World Health Organization. Noncommunicable Diseases (NCD) Country Profiles, 2014.
6. Health in Times of Transition: Trends in Population Health and Health policies in CIS countries. April 2013.
7. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20 (8): 1461–4.
8. Kotseva K, Wood D, De Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.Eur J Cardiovasc Prev Rehabil 2009; 16 (2): 121–37.
9. International Diabetes Federation. Diabetes Atlas Update 2013. Sixth edition. www.idf.org/diabetesatlas
10. Brenes GA, Kritchevsky SB, Mehta KM et al.Scared to death: results from the Health, Aging, and Body Composition study. Am J Geriatr Psychiatry 2007; 15 (3): 262–5.
11. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–48.
12. Randle PJ, Garland P, Hales C et al. The glucose-fatty acid cycle: its role in insulin sensitivity and metabolic disturbance of diabetes mellitus. Lancet 1963; 1: 785–9.
13. Uysal KT, Wiesbrock SM, Marino MW et al. Protection from obecity – induced insulin resistance in mice. Lacking TNF-alpha function. Nature 1997; 389: 610–4.
14. Ogawa Y. CNS Mediators of leptin action. Presented at the 60 th Scientific Sessions of the american diabetes association. June 13, 2000; San-Antonio, TEXAS.
15. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302: 128–39/
16. Straessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282 (6): 539–46.
17. Weber MA. Interrupting the RAS: the role of iACE and angiotensin II receptor antagonists in the treatment of hypertension Am J Hypertens 1999; 12 (12): 189–94.
18. Bossaller C, Auch-Schwelk W, Grafe M. Effects of converting enzyme inhibition on endothelial bradykinin metabolism and endothelial-dependent vascular relaxion. Agets Actions 1992; 38: 171–7.
19. Edarbi® (azilsartan medoxomil) prescribing information, Takeda Pharmaceuticals America, Inc. 2012. Data on file. Takeda Pharmaceutical Company Limited.
20. White WB et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413–20.
21. Bönner G et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertens 2010; 28: e283.
22. Kusumoto K et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Euro J Pharmacol 2011; 669: 84–93.
23. Iwai M. TAK – 536, a new receptor blocker, improved glucose intolerans and adipocyt differentiation. AJH 2007; 20: 579–86.
24. Клинические рекомендации «Диагностика и лечение артериальной гипертонии». Рабочая группа по подготовке текста: Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Кардиологический вестн. 2015; 1: 5–30. / Klinicheskie rekomendatsii «Diagnostika i lechenie arterial'noi gipertonii». Rabochaia gruppa po podgotovke teksta: Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Kardiologicheskii vestn. 2015; 1: 5–30. [in Russian]
25. Чазова И.Е., Фомин В.В., Разуваева М.А., Вигдорчик А.В. Эпидемическая характеристика резистентной и неконтролируемой артериальной гипертонии РЕГАТА-ПРИМА. Системные гипертензии. 2010; 7 (3): 34–41. / Chazova I.E., Fomin V.V., Razuvaeva M.A., Vigdorchik A.V. Epidemicheskaia kharakteristika rezistentnoi i nekontroliruemoi arterial'noi gipertonii REGATA-PRIMA. Systemic Hypertension. 2010; 7 (3): 34–41. [in Russian]
26. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801–8.
27. White W, Weber M, Sica D et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 HTN. HTN 2011; 57 (3): 413–20.
28. «Clinical Protocol on diagnosis and treatment of arterial hypertension» of the Republic of Kazakstan approved on November, 30, 2015.
2. Lewington S, Clarke R, Qizibash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adult in 61 prospective studies. Lancet 2002; 360: 1903–13.
3. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (Issue 9623): 1513–8.
4. Boitsov S.A., Balanova Iu.A., Shal'nova S.A. i dr. ot imeni issledovatelei. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovask. terapiia i profilaktika. 2014; 13 (4): 4–14. [in Russian]
5. World Health Organization. Noncommunicable Diseases (NCD) Country Profiles, 2014.
6. Health in Times of Transition: Trends in Population Health and Health policies in CIS countries. April 2013.
7. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20 (8): 1461–4.
8. Kotseva K, Wood D, De Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.Eur J Cardiovasc Prev Rehabil 2009; 16 (2): 121–37.
9. International Diabetes Federation. Diabetes Atlas Update 2013. Sixth edition. www.idf.org/diabetesatlas
10. Brenes GA, Kritchevsky SB, Mehta KM et al.Scared to death: results from the Health, Aging, and Body Composition study. Am J Geriatr Psychiatry 2007; 15 (3): 262–5.
11. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–48.
12. Randle PJ, Garland P, Hales C et al. The glucose-fatty acid cycle: its role in insulin sensitivity and metabolic disturbance of diabetes mellitus. Lancet 1963; 1: 785–9.
13. Uysal KT, Wiesbrock SM, Marino MW et al. Protection from obecity – induced insulin resistance in mice. Lacking TNF-alpha function. Nature 1997; 389: 610–4.
14. Ogawa Y. CNS Mediators of leptin action. Presented at the 60 th Scientific Sessions of the american diabetes association. June 13, 2000; San-Antonio, TEXAS.
15. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302: 128–39/
16. Straessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282 (6): 539–46.
17. Weber MA. Interrupting the RAS: the role of iACE and angiotensin II receptor antagonists in the treatment of hypertension Am J Hypertens 1999; 12 (12): 189–94.
18. Bossaller C, Auch-Schwelk W, Grafe M. Effects of converting enzyme inhibition on endothelial bradykinin metabolism and endothelial-dependent vascular relaxion. Agets Actions 1992; 38: 171–7.
19. Edarbi® (azilsartan medoxomil) prescribing information, Takeda Pharmaceuticals America, Inc. 2012. Data on file. Takeda Pharmaceutical Company Limited.
20. White WB et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413–20.
21. Bönner G et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertens 2010; 28: e283.
22. Kusumoto K et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Euro J Pharmacol 2011; 669: 84–93.
23. Iwai M. TAK – 536, a new receptor blocker, improved glucose intolerans and adipocyt differentiation. AJH 2007; 20: 579–86.
24. Klinicheskie rekomendatsii «Diagnostika i lechenie arterial'noi gipertonii». Rabochaia gruppa po podgotovke teksta: Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Kardiologicheskii vestn. 2015; 1: 5–30. [in Russian]
25. Chazova I.E., Fomin V.V., Razuvaeva M.A., Vigdorchik A.V. Epidemicheskaia kharakteristika rezistentnoi i nekontroliruemoi arterial'noi gipertonii REGATA-PRIMA. Systemic Hypertension. 2010; 7 (3): 34–41. [in Russian]
26. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801–8.
27. White W, Weber M, Sica D et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 HTN. HTN 2011; 57 (3): 413–20.
28. «Clinical Protocol on diagnosis and treatment of arterial hypertension» of the Republic of Kazakstan approved on November, 30, 2015.
2. Lewington S, Clarke R, Qizibash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adult in 61 prospective studies. Lancet 2002; 360: 1903–13.
3. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (Issue 9623): 1513–8.
4. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. от имени исследователей. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваск. терапия и профилактика. 2014; 13 (4): 4–14. / Boitsov S.A., Balanova Iu.A., Shal'nova S.A. i dr. ot imeni issledovatelei. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovask. terapiia i profilaktika. 2014; 13 (4): 4–14. [in Russian]
5. World Health Organization. Noncommunicable Diseases (NCD) Country Profiles, 2014.
6. Health in Times of Transition: Trends in Population Health and Health policies in CIS countries. April 2013.
7. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20 (8): 1461–4.
8. Kotseva K, Wood D, De Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.Eur J Cardiovasc Prev Rehabil 2009; 16 (2): 121–37.
9. International Diabetes Federation. Diabetes Atlas Update 2013. Sixth edition. www.idf.org/diabetesatlas
10. Brenes GA, Kritchevsky SB, Mehta KM et al.Scared to death: results from the Health, Aging, and Body Composition study. Am J Geriatr Psychiatry 2007; 15 (3): 262–5.
11. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–48.
12. Randle PJ, Garland P, Hales C et al. The glucose-fatty acid cycle: its role in insulin sensitivity and metabolic disturbance of diabetes mellitus. Lancet 1963; 1: 785–9.
13. Uysal KT, Wiesbrock SM, Marino MW et al. Protection from obecity – induced insulin resistance in mice. Lacking TNF-alpha function. Nature 1997; 389: 610–4.
14. Ogawa Y. CNS Mediators of leptin action. Presented at the 60 th Scientific Sessions of the american diabetes association. June 13, 2000; San-Antonio, TEXAS.
15. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302: 128–39/
16. Straessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282 (6): 539–46.
17. Weber MA. Interrupting the RAS: the role of iACE and angiotensin II receptor antagonists in the treatment of hypertension Am J Hypertens 1999; 12 (12): 189–94.
18. Bossaller C, Auch-Schwelk W, Grafe M. Effects of converting enzyme inhibition on endothelial bradykinin metabolism and endothelial-dependent vascular relaxion. Agets Actions 1992; 38: 171–7.
19. Edarbi® (azilsartan medoxomil) prescribing information, Takeda Pharmaceuticals America, Inc. 2012. Data on file. Takeda Pharmaceutical Company Limited.
20. White WB et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413–20.
21. Bönner G et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertens 2010; 28: e283.
22. Kusumoto K et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Euro J Pharmacol 2011; 669: 84–93.
23. Iwai M. TAK – 536, a new receptor blocker, improved glucose intolerans and adipocyt differentiation. AJH 2007; 20: 579–86.
24. Клинические рекомендации «Диагностика и лечение артериальной гипертонии». Рабочая группа по подготовке текста: Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Кардиологический вестн. 2015; 1: 5–30. / Klinicheskie rekomendatsii «Diagnostika i lechenie arterial'noi gipertonii». Rabochaia gruppa po podgotovke teksta: Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Kardiologicheskii vestn. 2015; 1: 5–30. [in Russian]
25. Чазова И.Е., Фомин В.В., Разуваева М.А., Вигдорчик А.В. Эпидемическая характеристика резистентной и неконтролируемой артериальной гипертонии РЕГАТА-ПРИМА. Системные гипертензии. 2010; 7 (3): 34–41. / Chazova I.E., Fomin V.V., Razuvaeva M.A., Vigdorchik A.V. Epidemicheskaia kharakteristika rezistentnoi i nekontroliruemoi arterial'noi gipertonii REGATA-PRIMA. Systemic Hypertension. 2010; 7 (3): 34–41. [in Russian]
26. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801–8.
27. White W, Weber M, Sica D et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 HTN. HTN 2011; 57 (3): 413–20.
28. «Clinical Protocol on diagnosis and treatment of arterial hypertension» of the Republic of Kazakstan approved on November, 30, 2015.
________________________________________________
2. Lewington S, Clarke R, Qizibash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adult in 61 prospective studies. Lancet 2002; 360: 1903–13.
3. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (Issue 9623): 1513–8.
4. Boitsov S.A., Balanova Iu.A., Shal'nova S.A. i dr. ot imeni issledovatelei. Arterial'naia gipertoniia sredi lits 25–64 let: rasprostranennost', osvedomlennost', lechenie i kontrol'. Po materialam issledovaniia ESSE. Kardiovask. terapiia i profilaktika. 2014; 13 (4): 4–14. [in Russian]
5. World Health Organization. Noncommunicable Diseases (NCD) Country Profiles, 2014.
6. Health in Times of Transition: Trends in Population Health and Health policies in CIS countries. April 2013.
7. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20 (8): 1461–4.
8. Kotseva K, Wood D, De Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.Eur J Cardiovasc Prev Rehabil 2009; 16 (2): 121–37.
9. International Diabetes Federation. Diabetes Atlas Update 2013. Sixth edition. www.idf.org/diabetesatlas
10. Brenes GA, Kritchevsky SB, Mehta KM et al.Scared to death: results from the Health, Aging, and Body Composition study. Am J Geriatr Psychiatry 2007; 15 (3): 262–5.
11. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–48.
12. Randle PJ, Garland P, Hales C et al. The glucose-fatty acid cycle: its role in insulin sensitivity and metabolic disturbance of diabetes mellitus. Lancet 1963; 1: 785–9.
13. Uysal KT, Wiesbrock SM, Marino MW et al. Protection from obecity – induced insulin resistance in mice. Lacking TNF-alpha function. Nature 1997; 389: 610–4.
14. Ogawa Y. CNS Mediators of leptin action. Presented at the 60 th Scientific Sessions of the american diabetes association. June 13, 2000; San-Antonio, TEXAS.
15. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302: 128–39/
16. Straessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282 (6): 539–46.
17. Weber MA. Interrupting the RAS: the role of iACE and angiotensin II receptor antagonists in the treatment of hypertension Am J Hypertens 1999; 12 (12): 189–94.
18. Bossaller C, Auch-Schwelk W, Grafe M. Effects of converting enzyme inhibition on endothelial bradykinin metabolism and endothelial-dependent vascular relaxion. Agets Actions 1992; 38: 171–7.
19. Edarbi® (azilsartan medoxomil) prescribing information, Takeda Pharmaceuticals America, Inc. 2012. Data on file. Takeda Pharmaceutical Company Limited.
20. White WB et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413–20.
21. Bönner G et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertens 2010; 28: e283.
22. Kusumoto K et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Euro J Pharmacol 2011; 669: 84–93.
23. Iwai M. TAK – 536, a new receptor blocker, improved glucose intolerans and adipocyt differentiation. AJH 2007; 20: 579–86.
24. Klinicheskie rekomendatsii «Diagnostika i lechenie arterial'noi gipertonii». Rabochaia gruppa po podgotovke teksta: Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Kardiologicheskii vestn. 2015; 1: 5–30. [in Russian]
25. Chazova I.E., Fomin V.V., Razuvaeva M.A., Vigdorchik A.V. Epidemicheskaia kharakteristika rezistentnoi i nekontroliruemoi arterial'noi gipertonii REGATA-PRIMA. Systemic Hypertension. 2010; 7 (3): 34–41. [in Russian]
26. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801–8.
27. White W, Weber M, Sica D et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 HTN. HTN 2011; 57 (3): 413–20.
28. «Clinical Protocol on diagnosis and treatment of arterial hypertension» of the Republic of Kazakstan approved on November, 30, 2015.
Авторы
Ю.В.Жернакова*, И.Е.Чазова от имени экспертов Координационного комитета
Институт клинической кардиологии им. А.Л.Мясникова ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России. 121552, Россия, Москва, ул. 3-я Черепковская, д. 15а
*juli001@mail.ru
A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15a
*juli001@mail.ru
Институт клинической кардиологии им. А.Л.Мясникова ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России. 121552, Россия, Москва, ул. 3-я Черепковская, д. 15а
*juli001@mail.ru
________________________________________________
A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15a
*juli001@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.